We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Genetic Testing and Blood-Based Monitoring Improve Understanding and Tracking of Prostate Cancer

By LabMedica International staff writers
Posted on 02 Jun 2025

Many men with aggressive prostate cancer face high recurrence rates despite undergoing treatment. More...

Now, findings of a new study suggest that specific gene mutations may be key to understanding these outcomes and could pave the way for more personalized therapies.

A Phase 2 clinical trial being conducted at UC Davis Comprehensive Cancer Center (Sacramento, CA, USA) is evaluating the use of niraparib (ZEJULA), a PARP inhibitor, administered before prostate cancer surgery. Researchers aim to determine whether this approach can prevent cancer recurrence, particularly in men whose tumors exhibit DNA repair gene mutations. In this pilot study, 11 men with high-risk prostate cancer and identified gene mutations received 200 mg of niraparib daily for 90 days prior to surgery. The median age of participants was 68 years, with a median prostate-specific antigen (PSA) level at diagnosis of 10.7 ng/mL. Genetic alterations observed included germline mutations in BRCA2, MSH6, and CHEK2, as well as somatic mutations in ATM, SPOP, KMT2C, and KMT2D.

While the treatment did not significantly reduce tumor size before surgery, the study highlighted the potential of genetic testing and blood-based monitoring in understanding and tracking prostate cancer. Notably, circulating tumor DNA (ctDNA) analysis proved effective in monitoring tumor evolution and resistance mechanisms in real time, according to the findings presented at the annual American Society of Clinical Oncology (ASCO) conference. The research team is now continuing to analyze the data to better understand why some cancers resist treatment and how to design future therapies that are more tailored to each individual.

“This study shows how complex prostate cancer can be, especially in men with certain gene mutations,” said Marc Dall’Era, chief of UC Davis Health’s Department of Urologic Surgery and lead researcher. “Although responses were variable, especially in patients with BRCA2 mutations, this study points to ctDNA as a promising tool to identify who might benefit from targeted neoadjuvant therapies.”

Related Links:
UC Davis Comprehensive Cancer Center


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining Management Software
DakoLink
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.